Patents Assigned to Vecta Ltd.
-
Patent number: 9370481Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: GrantFiled: April 19, 2011Date of Patent: June 21, 2016Assignee: Vecta, Ltd.Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
-
Patent number: 9278080Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: GrantFiled: April 27, 2010Date of Patent: March 8, 2016Assignee: Vecta, Ltd.Inventors: Aleksey Kostadinov, Ayelet David, Sabina Glozman
-
Patent number: 9233092Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more aliphatic carboxylic acid derivative molecules which activate parietal cells, wherein the derivatives possess delayed or sustained enhancement effect on the PPI activity compared to the non-derivatized acid molecules. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: GrantFiled: July 19, 2007Date of Patent: January 12, 2016Assignee: Vecta, Ltd.Inventors: Michael Marash, Aleksey Kostadinov, Tal Atarot
-
Patent number: 9132082Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+ ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: GrantFiled: May 14, 2009Date of Patent: September 15, 2015Assignee: Vecta, Ltd.Inventors: Aleksey Kostadinov, Tal Atarot, Michael Naveh
-
Patent number: 7981908Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: GrantFiled: May 14, 2008Date of Patent: July 19, 2011Assignee: Vecta, Ltd.Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
-
Patent number: 7803817Abstract: The present invention is related to oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and succinc acid as a parietal cell activator in the gastric lumen. The compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: GrantFiled: July 27, 2005Date of Patent: September 28, 2010Assignee: Vecta, Ltd.Inventors: Aleksey Kostadinov, Ayelet David, Sabina Glozman
-
Publication number: 20080248109Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: ApplicationFiled: May 14, 2008Publication date: October 9, 2008Applicant: VECTA, LTD.Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
-
Patent number: 7271146Abstract: The present invention relates to methods for treating pathological conditions associated with Helicobacter sp infections, specifically H. pylori infection. The present invention further relates to methods for treating pathologies characterized by excess gastric acid secretion. The methods of the present invention comprise oral administration of pentagastrin effective locally in the stomach in conjunction with a gastric proton pump inhibitor. It is disclosed herein for the first time that PG administered orally exerts a local effect in the stomach and may be used in combination with a PPI for treating pathological conditions characterized by excess gastric acid secretion and in pathological conditions associated with Helicobacter sp infections.Type: GrantFiled: October 14, 2003Date of Patent: September 18, 2007Assignee: Vecta Ltd.Inventor: Sabina Glozman
-
Patent number: 6815414Abstract: The invention relates to pharmaceutical compositions and methods for treating and/or preventing Helicobacter pylori-associated disorders, particularly disorders of the gastrointestinal tract. The pharmaceutical compositions comprise as active ingredient a therapeutically effective amount of a compound which inhibits the growth-enhancing effect of gastrin on H. pylori. The active ingredient may specifically be a compound which is capable of inhibiting gastrin uptake by H. pylori, and/or which is an antagonist of the human or H. pylori gastrin receptor.Type: GrantFiled: December 15, 2000Date of Patent: November 9, 2004Assignee: Vecta Ltd.Inventors: Michal Y. Chowers, Yehuda Chowers